OCD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand and agree to participate in the study on their own behalf.
- People aged 18 to 85 years.
- People who have been diagnosed with obsessive-compulsive disorder (OCD) according to standard diagnostic guidelines (DSM-5).
- People whose OCD symptoms score above 22 on a standard rating scale called the Yale-Brown Obsessive Compulsive Scale, indicating significant symptom severity.
- People who are taking psychiatric medications, provided the dose has been stable for at least 30 days before joining — those medications would continue throughout the study.
- People who have already tried at least two standard antidepressant medications at an appropriate dose and for long enough, as assessed by two psychiatrists.
- People who have previously had cognitive behavioural therapy (CBT) or another talking therapy specifically for OCD for at least 6 weeks.
Who may not be able to join:
- People who are pregnant or planning to become pregnant during the study.
- People who have a moderate or severe substance use disorder (other than cannabis or nicotine use) according to standard diagnostic guidelines (DSM-5).
- People with a known active seizure disorder (such as epilepsy), or a significant head injury where a brain scan has confirmed a lesion or area of damage.
- People with a medical condition that is currently unstable or poorly controlled.
- People for whom a 3-Tesla MRI scan would not be safe, for example due to having a pacemaker or certain other implanted devices that are not compatible with MRI.
- People who would not be able to reliably attend the required screening, treatment, and follow-up appointments.
- People with severe claustrophobia that would prevent them from undergoing an MRI scan.
- People with a history of a bleeding disorder or a condition affecting blood clotting.
- People taking blood-thinning or anti-clotting medications within certain time periods before treatment — specifically: antiplatelet drugs or warfarin-type medications within 7 days, newer oral anticoagulants within 72 hours, or heparin-based medications within 48 hours of treatment (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (416)-480-6954
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and Feasibility of FUS Neuromodulation in Participants With Treatment-Refractory Obsessive-Compulsive Disorder
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.